Learning more about Nevirapine

Antiretroviral therapy should nowadays beconsidered as a life-long proposition. As a consequence,previously unexpected, long-termadverse events, and particularly a greater risk ofcardiovascular complications, have become amajor concern among HIV-infected persons. Thisfear is particularly apparent among consumers ofprotease inhibitors (PI). A large number ofuncontrolled studies have compared different PIsparingregimens in order to assess their relativetoxicity and complexity. However, a direct comparisonbetween nevirapine (NVP)- and efavirenz(EFV)-containing regimens was still lacking. TwoSpanish studies have recently addressed thisissue.